10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features

Sparano, Joseph A. ; O'Neill, Anne ; Gray, Robert James ; Perez, Edith A. ; Shulman, Lawrence N. ; Martino, Silvana ; Badve, Sunil S. ; Baehner, Frederick L. ; Childs, Barrett H ; Yoshizawa, Carl N. ; Rowley, Steve ; Davidson, Nancy E. ; Shak, Steven ; Goldstein, Lori J.

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.1021-1021 [Periódico revisado por pares]

Texto completo disponível